Rhythm Pharmaceuticals (RYTM) Operating Expenses (2016 - 2025)
Historic Operating Expenses for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $104.0 million.
- Rhythm Pharmaceuticals' Operating Expenses rose 3476.33% to $104.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.5 million, marking a year-over-year decrease of 462.99%. This contributed to the annual value of $395.6 million for FY2024, which is 5112.75% up from last year.
- According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Operating Expenses is $104.0 million, which was up 3476.33% from $93.8 million recorded in Q2 2025.
- In the past 5 years, Rhythm Pharmaceuticals' Operating Expenses registered a high of $165.9 million during Q1 2024, and its lowest value of $34.4 million during Q1 2021.
- Over the past 5 years, Rhythm Pharmaceuticals' median Operating Expenses value was $65.5 million (recorded in 2023), while the average stood at $69.0 million.
- As far as peak fluctuations go, Rhythm Pharmaceuticals' Operating Expenses soared by 15914.69% in 2024, and later crashed by 5194.09% in 2025.
- Rhythm Pharmaceuticals' Operating Expenses (Quarter) stood at $52.8 million in 2021, then fell by 3.62% to $50.9 million in 2022, then grew by 28.7% to $65.5 million in 2023, then rose by 26.85% to $83.1 million in 2024, then rose by 25.11% to $104.0 million in 2025.
- Its Operating Expenses stands at $104.0 million for Q3 2025, versus $93.8 million for Q2 2025 and $79.7 million for Q1 2025.